Last week we looked at physician burnout, where it actually comes from in dermatology practice and why the usual wellness frameworks miss the point. The conclusion most clinicians arrived at was the same one the data has been pointing to for years: burnout in this specialty is rarely about the clinical work. It's about everything that surrounds the clinical work: the prior auth queue, the sample request that takes 40 minutes, the after-hours documentation, the patient who calls back two weeks later because they never filled the prescription.

That last part is where this issue lives. Patients don't fail treatment as often as we think. Treatment fails to reach them, and the same access gap that quietly loses outcomes is the one quietly burning out the clinicians trying to close it. In dermatology, where therapeutic windows are long, regimens are layered, and out-of-pocket costs are unusually visible, this is where the work piles up and where the patients fall through.

Here are five clinical mistakes that turn a good prescription into a treatment that never starts.

This issue is sponsored by DocUpdate, a free HIPAA-compliant digital assistant built by physicians for physicians. Their tools, including an intelligent prescribing assistant, AI medical translator for 23+ languages, and pharmaceutical concierge, are designed to give clinicians time back. More at https://docupdate.onelink.me/j4xR/DermPCP 

Mechanism. Health literacy data consistently shows that roughly one in three U.S. adults has limited health literacy, and comprehension drops further when the encounter is rushed, in a second language, or involves multi-step topical regimens (vehicle, frequency, sequence, contact time). Nodding is a social cue, not a comprehension check.

Evidence. Teach-back methodology, asking the patient to explain the plan back in their own words, has been associated with measurable improvements in adherence and reductions in error across chronic disease management, including dermatologic regimens with complex application instructions.

Patient counseling script. "Before you go, walk me through how you'll use this tonight. Which one goes on first, and how long do you wait before the next step?" If they can't answer, the regimen is not yet prescribed. It's still being explained.

Mechanism. Formulary exclusions, tier placement, prior authorization triggers, and quantity limits vary by plan and change quarterly. A medication that is covered for one patient may require step therapy for another with the same diagnosis. Patients rarely know this until they're at the counter, and by then the encounter is over.

Evidence. Primary non-adherence, meaning patients never filling a new prescription, is estimated in the 20–30% range across specialties, with cost and prior auth surprises among the most-cited drivers. Topical biologics, JAK inhibitors, and newer atopic dermatitis agents are particularly exposed.

Patient counseling script. "If the pharmacy tells you this isn't covered or costs more than [threshold], don't pay and don't walk away. Message us first. There are almost always alternatives or assistance programs."

Mechanism. When clinically complex content (a diagnosis, a treatment plan, a return-precaution) is delivered through a family member, a free consumer translation app, or improvised English, the error rate is non-trivial and asymmetric. Patients lose the parts that matter most: when to stop the medication, what side effect requires a call, what counts as worsening.

Evidence. Studies of limited-English-proficient patients consistently show worse adherence, more ED utilization for ambulatory-sensitive conditions, and lower satisfaction. Professional medical interpretation reduces this gap; ad-hoc translation does not.

Patient counseling script. "I want to make sure nothing about your treatment plan is unclear because of language. We're going to use a medical translator for the important parts: diagnosis, how to use the medication, and when to call us."

Mechanism. The infrastructure that determines whether a patient actually starts therapy (manufacturer samples, copay cards, patient assistance program enrollment, MSL contacts, starter kits) sits across a fragmented network of rep relationships, manufacturer portals, and email threads. The clinical decision takes 90 seconds. The access workflow takes 40 minutes, often performed after hours by the prescriber.

Evidence. Practice-management surveys consistently identify access logistics as a leading driver of clinician administrative burden, and a leading reason patients delay or skip initiation of newer therapies. The bottleneck is not clinical judgment; it's coordination.

Patient counseling script. "I'm going to request a starter sample and a copay card before you leave today. If anything stalls between now and your fill date, our team will be the ones following up, not you."

Mechanism. No call from the patient and no call from the pharmacy is not evidence of treatment success. It is, more often, evidence that the patient is no longer engaged: they didn't fill it, they filled it and stopped, they switched to something a friend recommended, or they're waiting for the next visit to bring it up. Without a structured follow-up touchpoint, this is invisible until the next exacerbation.

Evidence. Across dermatologic conditions with chronic or relapsing courses (atopic dermatitis, psoriasis, acne, rosacea, hidradenitis suppurativa), adherence at three months is consistently lower than self-report would suggest, and lower still in patients with cost pressure or limited language access.

Patient counseling script. "I don't expect you to be perfect with this. I expect you to tell me what's getting in the way. A short message in two weeks, even just 'still using it' or 'I stopped,' is more useful to me than a perfect chart."

Three forces are tightening the access gap simultaneously. Specialty dermatologic agents are launching with higher list prices and tighter prior auth gates. Patient populations are increasingly multilingual, with limited-English-proficient patients underrepresented in the data we use to design care pathways. And clinician time per patient continues to compress, even as the administrative load behind each prescription grows.

This is the same load we identified last week as the real driver of burnout. The clinicians who are protecting outcomes, and protecting themselves, in this environment are not the ones working harder. They are the ones who have moved access work out of the inbox and into a single workflow they can act on in the room.

Interested in reaching our 8,000+ subscribers?

Click here to learn more!

https://go.dermforprimarycare.com/newsletter-sponsor-lp 

We have created this FREE Guide for you:

Take one of our modules!

Next week we're sitting down with one of the more quietly important relationships in clinical practice: the pharmaceutical representative. The conversation around reps tends to swing between two unhelpful extremes, but the day-to-day reality is more grounded. Reps are often the reason a patient walks out with a starter sample that bridges them to a real fill, the reason a copay card lands in the right hands at the right time, and the reason a clinician hears about a new indication or formulation before it shows up in a journal. We'll talk honestly about where the relationship works, where it needs guardrails, and how to get the most clinical value out of it for the patients sitting in front of you. 

See you next Thursday, DERM Community.

Until then, stay curious and keep translating science into realistic hope.

Have a topic you'd like us to cover? Reply to this email.

DERM Community | Derm for Primary Care Team